undamentalytics Newsletter
Sign in

Genedx Holdings Corp. revenue

Genedx Holdings Corp.'s revenue was $428m in fiscal 2025, up 40.0% on the year before. Since fiscal 2019 ($196m) it has grown at a compound 13.9% a year. Over the last twelve months it was $454m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue196179212235203305428454
Growth on the year before—−8.6%+18.3%+10.6%−13.7%+50.8%+40.0%—
Gross profit834−17−2790194298315

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Gene Dx $423M 99.0% ▲ 40.0%
All Other Segments $4.5M 1.0% ▲ 41.0%
Products and services
Line of business Revenue Share YoY
Diagnostic Test $417M 97.1% ▲ 37.9%
Diagnostic Test Third Party Insurance $345M 82.9% ▲ 47.1%
Diagnostic Test Institutional Customers $70.1M 16.8% ▲ 7.6%
Other $10.9M 2.5% ▲ 230.1%
Diagnostic Test Self Pay $1.4M 0.3% ▼ 41.9%

From Genedx Holdings Corp.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Technology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Genedx Holdings Corp. $454m 25.4% 24.3%
Phreesia, Inc. $508m 12.9% 16.7%
Healthstream Inc $321m 8.8% 5.4%
Doximity, Inc. $656m 11.2% 14.5%
Health Catalyst, Inc. $292m -7.5% 0.9%
Goodrx Holdings, Inc. $785m -1.8% 1.8%

Compare with peers

Head to head: PHR vs WGSHSTM vs WGSDOCS vs WGS

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Genedx Holdings Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Genedx Holdings Corp.